A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

NCT04740814 PHASE1 COMPLETED Results posted

The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.

Details

Lead sponsor	UCB Biopharma SRL
Phase	PHASE1
Status	COMPLETED
Enrolment	33
Start date	Thu Feb 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jun 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Rheumatoid Arthritis

Interventions

• Certolizumab pegol

Countries

United States